

Short communication

## Combination therapy with zidovudine, didanosine and saquinavir

A.C. Collier<sup>a</sup>, R.W. Coombs<sup>a,\*</sup>, D.A. Schoenfeld<sup>a</sup>, R. Bassett<sup>a</sup>, A. Baruch<sup>b</sup>, L. Corey<sup>a</sup>

<sup>a</sup>*The AIDS Clinical Trials Group Protocol 229 Team, NIAID, Bethesda MD, USA*

<sup>b</sup>*Hoffmann-La Roche, Nutley, NJ, USA*

---

### Abstract

The goal of AIDS Clinical Trials Group (ACTG) Protocol 229 was to evaluate the shorter term (24 week) and longer term (48 week) safety and activity of the HIV-1 proteinase inhibitor saquinavir in combination with zalcitabine (ddC) and zidovudine (ZDV) versus saquinavir in combination with ZDV versus ddC in combination with ZDV. This study confirms and extends the conclusions from the first 24 weeks of this study and showed that in subjects with extensive prior antiretroviral experience, the triple combination of saquinavir, ddC and ZDV was well-tolerated, safe and remained superior to the other double drug regimens as measured by CD4+ cell counts, quantitative HIV-1 microculture and plasma HIV-1 RNA levels.

**Keywords:** Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; Combination therapy; CD4+ cell; Quantitative HIV-1 microculture; HIV-1 RNA

---

---

\* Departments of Laboratory Medicine and Medicine, University of Washington, Virology Office, Room 9301, Pacific Medical Center, 1200 12th Ave. S. Seattle, WA 98144, USA.  
Tel.: +1 206 6214342; fax: +1 206 6214178.